The antigen CD133 is regarded as an important marker for the identification and enrichment of primitive stem and progenitor cells from hematopoietic tissue such as adult blood and bone marrow aspirates. Investigations in the area of tissue regeneration focus mostly on the enrichment of autologous CD133+
cells from bone marrow aspirate. These enriched and well-defined stem cells are being examined in various diseases such as cardiac
, peripheral artery, and liver diseases
. The development of an improved device, the CliniMACS® Prodigy
, has led to the enrichment procedure being streamlined and reduced to less than three hours. This new technology enables preparation of a specific cell product under sterile conditions and a direct transfer of the cells for further applications.
In addition, the CD34 antigen has been used in applications related to hematopoietic diseases and also been studied in the field of tissue regeneration. A variety of clinical-grade products are available for the enrichment of CD34+ stem cells
mostly from mobilized leukapheresis.